To determine the natural course of zinc protoporphyrin/heme ratio (ZnPP/H) and its role in the detection of iron deficiency (ID) and iron-deficiency anemia (IDA) in the first 4 months of life in moderately preterm infants. STUDY DESIGN: ZnPP/H was measured at 1 week, 6 weeks and 4 months postnatal age in a prospective cohort of 161 Dutch infants born at a gestational age of 32+0 to 36+6 weeks who did not receive an erythrocyte transfusion or iron supplementation. RESULTS: ZnPP/H levels decreased in the first 6 weeks and increased thereafter. 
INTRODUCTION
Preterm infants are prone to develop iron deficiency (ID) and irondeficiency anemia (IDA) in the first 4 months of life due to lower iron stores at birth compared with term infants, rapid growth and iron losses by phlebotomy after birth.
1,2 ID, even without anemia, may cause irreversible morbidity in preterm infants, such as impaired neurological development. 3 Iron supplementation is therefore recommended in preterm infants with a birth weight o1800 g. 4, 5 However, these recommendations are mostly based on studies in infants born at o32 weeks of gestational age (GA). Information on iron requirements in moderately preterm infants born at 32-37 weeks GA, accounting for the greater relative proportion of preterm births, is limited. 2, 6, 7 Providing iron supplementation in each preterm infant, regardless of its iron status, might cause iron overload in infants with sufficient iron stores, which is associated with an increased risk of infection and impaired growth. 1, 8 To be able to individualize iron supplementation in moderately preterm infants, it is important to differentiate infants at risk for ID and those who are not and might be harmed by iron overload.
Early recognition of moderately preterm infants at risk for ID is a clinical challenge. Ferritin is a widely used parameter representing body iron stores, but its interpretation can be difficult as it increases during infection and inflammation. 9 The zinc protoporphyrin/heme ratio (ZnPP/H) may be a reliable alternative to screen for ID because it is not influenced by acute inflammation. 10, 11 ZnPP/H is an indicator of iron-restricted erythropoiesis. Without sufficient amounts of iron available, zinc will be incorporated in protoporphyrin IX in red blood cells, causing an increase in ZnPP/H levels. [11] [12] [13] As moderately preterm infants are at risk to develop ID and IDA in the first 4 months of life, one might expect increasing ZnPP/H levels after birth. However, the natural course of ZnPP/H in the first months of life and the association of ZnPP/H with the development of ID and IDA is not known in these infants. Therefore, we addressed the following questions in a cohort of Dutch moderately preterm infants screened for ID and IDA, who did not receive an erythrocyte transfusion or iron supplementation: (1) What is the natural course of ZnPP/H in the first 4 months of life? (2) Are ZnPP/H levels higher in moderately preterm infants with ID or IDA at 4 months of age compared with those who are not iron deficient? (3) What is the influence of demographical and clinical neonatal and maternal factors, which might have a negative impact on the iron status of the newborn infants, on the level of ZnPP/H at 4 months of age? (4) Are higher ZnPP/H levels associated with lower hemoglobin (Hb) and ferritin concentrations and higher reticulocyte counts at 4 months of age?
METHODS

Study design and population
A prospective cohort study on iron status in moderately preterm infants born between 32+0 and 36+6 weeks GA was conducted in three level II hospitals in the Netherlands.
14 Eligible infants were identified from delivery records. Exclusion criteria were congenital malformations, chronic or inherited metabolic diseases, hemoglobinopathies, active blood loss during delivery/major bleeding, twin-to-twin transfusion syndrome, hemolytic disease or erythrocyte transfusions in the first 4 months of life. Pediatricians were allowed to prescribe iron supplementation if they considered this to be appropriate. Infants receiving iron supplementation were not included in the analyses. The relation between ZnPP/H levels and ID and IDA was studied in infants who had normal C-reactive protein (CRP) concentrations (o5 mg l − 1 ) because the diagnoses of ID and IDA were based on ferritin concentrations, an acute-phase protein that might be elevated during infection or inflammation. Written informed consent was obtained from all parents of the infants included. The study was approved by the Medical Ethics Committee of South-West Holland.
Data collection
Venous blood (3 ml) was collected in the first week of life and at routine follow-up visits at the postnatal age of 6 weeks and 4 months. These blood samples were analyzed for ZnPP/H, Hb, ferritin, reticulocyte count and CRP.
Information on maternal conditions that might have a negative influence on the iron status of the newborn infants (gestational diabetes, pregnancy-induced hypertension, smoking habits and iron supplementation during pregnancy) 15, 16 was collected from medical files. Gestational diabetes was diagnosed based on an abnormal oral glucose test when fasting plasma glucose was ⩾ 7.0 mmol l − 1 (126 mg dl − 1 ) or 2 h plasma glucose was ⩾ 11.1 mmol l − 1 (200 mg dl − 1 ). 17 Pregnancy-induced hypertension was defined as a blood pressure of 4140 mm Hg systolic or 490 mm Hg diastolic, either of those measured at least twice after the twentieth week of gestation in women with normal blood pressures before pregnancy. 18 Postnatal data of the infants (Apgar scores, birth weight, GA, neonatal diagnoses and feeding practices) were collected from medical files. Infants were identified as small for GA when their birth weight was less than the 10th percentile using Dutch references. 19 Anthropometric data were recorded after birth and when visiting the outpatient clinic for routine follow-up. Growth rate at follow-up visits was calculated as weight gain in grams relative to birth weight (growth rate = weight at 4 months/ birth weight).
Definitions
ID at the age of 4 months was defined as a ferritin concentration o20 μg l . 1,20 Infants described as normal had neither ID nor IDA. ZnPP/H was displayed as micromol mol − 1 heme; no reference values were available.
Biochemical tests
Hb and reticulocyte count were determined using a Sysmex XE-2100 (Sysmex Corporation, Kobe, Japan) automated hematology analyzer. Ferritin and CRP concentrations were analyzed in plasma, using a Unicel DxI 800 immunochemistry analyzer (Beckman Coulter, Fullerton, CA, USA).
ZnPP/H was analyzed in whole blood after washing with phosphate- Figure 1 . Flow chart of study population and the number of infants included in the analyses. Reasons for drop-out before 4 months of age: moved (n = 4); did not came to the routine checks in the outpatient clinic (n = 3); parents withdrew consent to draw extra blood for study purposes (n = 9), and unknown (n = 2). CRP, C-reactive protein; ID, iron deficiency; IDA, iron-deficiency anemia; ZnPP/H, zinc protoporphyrin/ heme ratio.
buffered saline by using the AVIV ZPP Hematofluorometer model 206D (AVIV Biomedical, Lakewood, NJ, USA). The interassay variation on the normality cutoff value is 4.4% and the intra-assay variation is 5.6% for this analyzer.
Statistical analysis
Statistical analyses were performed by using SPSS (version 22; SPSS, Chicago, IL, USA). In this paper, we describe subanalyses of a study to evaluate iron status and the incidence of ID and IDA in preterm infants. 14 The study was not specifically powered to detect changes in ZnPP/H levels. Outcome variables were checked for normality using histograms and the Kolmogorov-Smirnov test. ZnPP/H and ferritin levels were not normally distributed and therefore logarithmic transformation of these parameters was used to calculate the mean and s.d. When describing the results, the outcomes of transformed variables were converted back to their original units.
To compare the ZnPP/H levels between infants with ID or IDA and normal infants at 4 months of age, we used the Student's independent T-test or the Mann-Whitney U-test, depending on the distribution of the data. Subsequently, in case of a difference in ZnPP/H levels between infants with ID or IDA and normal infants, a receiver operating characteristic curve was constructed to look for a cutoff value of ZnPP/H at 1 week of age predictive of the risk to develop ID or IDA at 4 months of age.
At 4 months of age, we analyzed demographical and clinical factors as well as laboratory parameters that possibly influence ZnPP/H levels. 12, 21 First, a linear univariate regression analysis was carried out for the following factors: (1) infant factors: GA, birth weight, gender, Apgar score at 5 min of age, growth rate at 4 months of age, and duration of breastfeeding, (2) maternal factors: smoking during pregnancy, pregnancy-induced hypertension, gestational diabetes, and iron supplementation during pregnancy, and (3) iron status parameters: Hb, reticulocyte count, and ferritin. Second, in multivariate analysis with a backward Wald method, we included the demographical and clinical factors and laboratory parameters associated with ZnPP/H in univariate analysis with a P-value o0.10.
Statistical significance was defined as a P-valueo0.05.
RESULTS
Study population
Of the 200 infants eligible for inclusion, 39 infants were excluded ( Figure 1) . Characteristics of the remaining 161 infants included in the study are shown in Table 1 . Mean GA at birth was 34.9 (s.d. 1.1) weeks and mean birth weight was 2,297 (s.d. 459) g. Three different analyses were performed to answer the four research questions. Figure 1 shows the number of infants included in these analyses. Natural course of ZnPP/H Figure 2 shows the course of ZnPP/H at three time points in the first 4 months of life in the study population. After an initial decline between the first and sixth week of life (P o 0.01), ZnPP/H levels increased between 6 weeks and 4 months of age (P = 0.036).
Comparing ZnPP/H levels in infants with ID or IDA and normal infants At 4 months of age, after excluding infants with CRP45 mg l − 1 (n = 15) or a missing CRP value (n = 17), 129 infants were analyzed for ID and IDA. ID was present in 27 (21.3%) infants and IDA in 11 (8.5%) infants (Table 1) .
ZnPP/H levels were higher in infants with IDA compared with normal infants (mean (s. A receiver operating characteristic curve was constructed for ZnPP/H levels at 1 week of age and IDA at the age of 4 months. The area under the curve was 0.7 (95% confidence interval: 0.5-0.8) with a P-value of 0.11 and the most optimal cutoff value would be a ZnPP/H level of 187.5 micromol mol − 1 heme with a sensitivity of 60% and specificity of 78%. (Figure 3 ) With this cutoff value, the positive predicting value is 21.6% and the negative predicting value is 95.4%.
Factors influencing ZnPP/H levels at 4 months of age
Results of linear regression analyses of demographical and clinical factors and laboratory parameters possibly influencing ZnPP/H levels at 4 months of age are presented in Table 2 . Multivariate analyses showed that ZnPP/H levels were positively associated with growth rate in the first 4 months. Infants of mothers with hypertension during pregnancy had lower ZnPP/H levels at 4 months of age compared with infants of mothers with no pregnancy-induced hypertension. Furthermore, infants with lower Hb levels had significantly higher ZnPP/H levels. However, no associations between ferritin and reticulocyte count with ZnPP/H levels were found at 4 months of age. In addition, ZnPP/H and CRP levels were not associated in our study population.
DISCUSSION
In this study, we describe the natural course of ZnPP/H during the first 4 months of life in a cohort of Dutch moderately preterm ZnPP/H ratio and its role in ID and IDA in preterm infantsinfants who did not receive an erythrocyte transfusion or iron supplementation. ZnPP/H levels show an initial decline between 1 week and 6 weeks of age and an increase between 6 weeks and 4 months of age. Furthermore, at the age of 4 months ZnPP/H levels were higher in the 11 (8.5%) infants with IDA compared with normal infants. However, no differences in ZnPP/H were observed in the 27 (21.3%) infants with ID without anemia and normal infants. At 4 months of age, higher ZnPP/H levels were associated with a higher growth rate and lower Hb levels. In addition, maternal hypertension during pregnancy was associated with lower ZnPP/H levels at 4 months of age. Natural course of ZnPP/H As ZnPP/H is an indicator of iron available for erythropoiesis, 12, 13 one would expect an increase in ZnPP/H levels after birth representing higher iron needs due to rapid growth and iatrogenic iron losses due to frequent blood sampling. However, we found a decrease in ZnPP/H levels in the first 6 weeks that returned to baseline levels thereafter. The initial decrease in ZnPP/H levels could be explained by the breakdown of fetal Hb. It is known that healthy term infants have sufficient amounts of iron available due to the recirculation of iron derived from fetal Hb, until their birth weight has doubled at 6 months of age. In our study population, birth weight has already doubled at 6 weeks of age with a simultaneous decrease of iron available for erythropoiesis and a subsequent increase of ZnPP/H levels from 6 weeks of age onwards.
The natural course of ZnPP/H in our study differs from that described by Griffin et al. 22 They found a gradual decline of ZnPP/H in the first year of life in preterm, low birth weight infants. However, 40% of the infants included in that study received an erythrocyte transfusion. Erythrocyte transfusions decrease ZnPP/H levels 11, 12 and this might explain the different course of ZnPP/H in the study of Griffin et al. 22 compared with our study. We have found that ZnPP/H levels measured in the first week of life were higher than ZnPP/H levels in the cord blood of a comparable cohort of preterm infants. 23 The higher ZnPP/H levels in our study population might be a reflection of intrauterine growth restriction, intrauterine hypoxia and maternal conditions that can lead to impaired placental function with decreased mother-to-fetus iron supply. Insufficient iron supply to the fetus stimulates erythropoiesis and increases ZnPP/H levels. 15, 16 In the study by Lorenz et al., 23 infants who were exposed to these prenatal conditions were excluded.
Comparing ZnPP/H levels in infants with ID or IDA and normal infants We have showed that infants diagnosed with IDA at 4 months of age had higher levels of ZnPP/H. As described in other studies, no association was observed between high ZnPP/H levels and low ferritin levels in infants with ID but without anemia. 22 A possible explanation for the absence of an association with ferritin is that ZnPP/H directly reflects the amount of iron available for the erythropoiesis, whereas ferritin represents the amount of stored iron in the body. ZnPP/H seems to be a good representative of iron available for erythropoiesis, but it is not useful as an indicator of iron stores.
Factors influencing ZnPP/H levels at 4 months of age As expected, ZnPP/H levels were higher at 4 months of age in faster growing infants. High growth velocity has been reported as a risk factor for ID and IDA, 1, 23 because an increase in weight and subsequently expanding blood volume increases the requirement of iron for erythropoiesis. 12, 21 We found lower ZnPP/H levels in the infants of mothers with pregnancy-induced hypertension. One could expect higher ZnPP/H levels because of insufficient iron transport due to pathophysiological changes in the placenta that have been described in the mothers with hypertension during pregnancy. On the other hand, similar changes of the placenta may cause chronic intrauterine hypoxia and an increased erythropoiesis in the fetus. 16 Higher Hb levels, which we found at 1 week of age in infants born to mothers with pregnancy-induced hypertension, probably reflect intrauterine hypoxia and increased erythropoiesis and might have contributed to the lower levels of ZnPP/H in these infants at 4 months of age.
Strengths and limitations
To the best of our knowledge, this is the first study to describe the natural course of ZnPP/H in the first 4 months of life in moderately preterm infants. Infants were diagnosed with ID or IDA at 4 months of age based on the World Health Organization criteria by taking CRP levels, and therefore inflammation, into account. The main limitation that needs to be addressed is the limited sample size of our population, which is further accentuated by missing data at the three time points that measurements were performed. The number of patients might therefore be too small to detect an association between ZnPP/H and feeding practices, gestational diabetes, ferritin and reticulocyte count. On the other hand, relatively few of the eligible infants were omitted from the analysis that makes it more likely to apply our conclusions to a greater proportion of near-term premature infants. Although we did find higher ZnPP/H levels in infants with IDA at 4 months of age, we were not able to determine reliable cutoff values for ZnPP/H at 1 week of age to predict IDA at 4 months of age as can be seen in the receiver operating characteristic curve we constructed (Figure 3 ). This can be attributed to the limited number of patients with IDA in our cohort. In two previous publications on iron status parameters in the same infants, 14,24 the predictive value of ferritin and hepcidin are described. Probably, a combination of iron status parameters is valuable to predict the risk for ID after birth. This is considered a topic for further research. Furthermore, larger studies are needed to investigate whether or not early ZnPP/H values are useful to predict ID or IDA at 4 months of age.
CONCLUSION
ZnPP/H reflects iron available for erythropoiesis in the first 4 months of life in moderately preterm infants and can be of additional value to detect infants with IDA due to iron-deficient erythropoiesis at 4 months of age, even with sufficient iron stores. The value of early ZnPP/H measurements to predict IDA at 4 months of age remains to be established.
